For Research Use Only

AKT2 Polyclonal antibody Catalog Number:28113-1-AP 3 Publications

Antibodies | ELISA kits | Proteins www.ptglab.com


Basic Information	Catalog Number: 28113-1-AP	GenBank Accession Numb BC 120994		<mark>Aethod:</mark> ity purification
	Concentration:	GenelD (NCBI):	Recommende	
	550 µg/ml	208	WB 1:500-1:1	
	Source: Rabbit	UNIPROT ID: P31751	IHC 1:50-1:50 IF/ICC 1:50-1	
	Isotype:			
	lgG Immunogen Catalog Number:	v-akt murine thymoma viral oncogene homolog 2		
	AG27005	Observed MW: 56 kDa		
Applications	Tested Applications:	Pc	Positive Controls:	
	Cited Applications:		B : NIH/3T3 cells, mouse li	ver tissue
			C : human liver tissue,	Jman liver tissue,
	Species Specificity: IF/ICC : NIH/3T3 cells, human, mouse			
	Cited Species: human, mouse			
	Note-IHC: suggested antige TE buffer pH 9.0; (*) Alterno retrieval may be performed buffer pH 6.0	atively, antigen		
	AKT2 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, ar which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis and their activation has been observed in a wide variety of cancers. AKT2 is mainly involved in cancer cell survival, apoptosis inhibition, migration and invasion(PMID:21979951). Defects in AKT2 are a cause of susceptibility to brea cancer (BC). AKT2 promotes metastasis of tumor cells without affecting the latency of tumor development. And defects in AKT2 are a cause of non-insulin-dependent diabetes mellitus (NIDDM) and hypoinsulinemic hypoglycemia with hemihypertrophy (HIHGHH). The full length protein has four glycosylation sites.			
Background Information	which regulate many processes in their activation has been observed apoptosis inhibition, migration ar cancer (BC). AKT2 promotes metas defects in AKT2 are a cause of non	d in a wide variety of cancers. Id invasion(PMID:21979951). I Itasis of tumor cells without a -insulin-dependent diabetes r	AKT2 is mainly involved i Defects in AKT2 are a cause ffecting the latency of tum nellitus (NIDDM) and hypo	and angiogenesis and n cancer cell survival, e of susceptibility to bre or development. And pinsulinemic
Background Information	which regulate many processes in their activation has been observed apoptosis inhibition, migration ar cancer (BC). AKT2 promotes metas defects in AKT2 are a cause of non hypoglycemia with hemihypertro	d in a wide variety of cancers. Id invasion(PMID:21979951). I Itasis of tumor cells without a -insulin-dependent diabetes r	AKT2 is mainly involved i Defects in AKT2 are a cause ffecting the latency of tum nellitus (NIDDM) and hypo	and angiogenesis and n cancer cell survival, e of susceptibility to bre or development. And pinsulinemic
	which regulate many processes in their activation has been observed apoptosis inhibition, migration ar cancer (BC). AKT2 promotes metas defects in AKT2 are a cause of non hypoglycemia with hemihypertro	d in a wide variety of cancers. Id invasion(PMID:21979951). I tasis of tumor cells without at -insulin-dependent diabetes r phy (HIHGHH). The full length Pubmed ID Journal	AKT2 is mainly involved i Defects in AKT2 are a cause ffecting the latency of tum nellitus (NIDDM) and hypo	and angiogenesis and n cancer cell survival, e of susceptibility to bre or development. And pinsulinemic tion sites.
	which regulate many processes in their activation has been observed apoptosis inhibition, migration ar cancer (BC). AKT2 promotes metas defects in AKT2 are a cause of non hypoglycemia with hemihypertro Author Zhi-Da Zhang	d in a wide variety of cancers. Id invasion(PMID:21979951). I tasis of tumor cells without a -insulin-dependent diabetes r phy (HIHGHH). The full length Pubmed ID Journal	AKT2 is mainly involved i Defects in AKT2 are a cause ffecting the latency of tum nellitus (NIDDM) and hypo protein has four glycosyla hem Cell Biol	and angiogenesis and n cancer cell survival, e of susceptibility to bre or development. And pinsulinemic ttion sites. Application
	which regulate many processes in their activation has been observed apoptosis inhibition, migration ar cancer (BC). AKT2 promotes metas defects in AKT2 are a cause of non hypoglycemia with hemihypertro Author Zhi-Da Zhang Nannan Sha	d in a wide variety of cancers. Id invasion(PMID:21979951). I itasis of tumor cells without at -insulin-dependent diabetes r phy (HIHGHH). The full length Pubmed ID Journal 35219877 Int J Bioc	AKT2 is mainly involved i Defects in AKT2 are a cause ffecting the latency of tum nellitus (NIDDM) and hypo protein has four glycosyla hem Cell Biol	and angiogenesis and n cancer cell survival, e of susceptibility to bre or development. And pinsulinemic ttion sites. Application WB

 For technical support and original validation data for this product please contact:

 T: 4006900926
 E: Proteintech-CN@ptglab.com
 W: ptgcn.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.


Selected Validation Data




Various lysates were subjected to SDS PAGE followed by western blot with 28113-1-AP (AKT2 antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.



Immunohistochemical analysis of paraffinembedded human liver tissue slide using 28113-1-AP (AKT2 antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunofluorescent analysis of (-20°C Ethanol) fixed NIH/3T3 cells using AKT2 antibody (28113-1-AP) at dilution of 1:100 and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L).



28113-1-AP(AKT2),FITC-H

1X10^6 NIH/3T3 cells were intracellularly stained with 0.4 ug Anti-Human AKT2 (28113-1-AP) and Coralite®488-Conjugated Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Control Antibody. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).